Avastin, Jevtana And Faslodex Among Stada’s 2021 Complex Offerings
Stada Enjoys 8% Top Line Growth In 2021 But Adjusted EBITDA Dips By 1%
Germany’s Stada completed on several strategic milestones in 2021, including launches, approvals and filings for its burgeoning biosimilars business. Reporting financial results for 2021, Stada disclosed the latest on plans to submit partner Xbrane’s ranibizumab biosimilar with the US FDA.
You may also be interested in...
Stada has launched abiraterone film-coated tablets, a generic version of Janssen’s Zytiga, in 21 markets across Europe as protection for the branded treatment for metastatic prostate cancer expired.
A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.
Stada has announced the appointment of former Sandoz executive Christine Berndt as head of global development for specialty and biosimilar products, replacing Michael Mack.